A Phase III Open, Randomized, Parallel, Multi-center Study in Children Aged 6 - 35 Months to Compare the Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V Administered According to a 0/4 Week Schedule.
Phase of Trial: Phase III
Latest Information Update: 17 May 2013
At a glance
- Drugs Influenza virus vaccine liposomal (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Crucell
- 07 Mar 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Nov 2010 New trial record